Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
A partial form of recessive STAT1 deficiency in humans
Ariane Chapgier, … , Dan Engelhard, Jean-Laurent Casanova
Ariane Chapgier, … , Dan Engelhard, Jean-Laurent Casanova
Published May 11, 2009
Citation Information: J Clin Invest. 2009;119(6):1502-1514. https://doi.org/10.1172/JCI37083.
View: Text | PDF
Research Article Immunology

A partial form of recessive STAT1 deficiency in humans

  • Text
  • PDF
Abstract

Complete STAT1 deficiency is an autosomal recessive primary immunodeficiency caused by null mutations that abolish STAT1-dependent cellular responses to both IFN-α/β and IFN-γ. Affected children suffer from lethal intracellular bacterial and viral diseases. Here we report a recessive form of partial STAT1 deficiency, characterized by impaired but not abolished IFN-α/β and IFN-γ signaling. Two affected siblings suffered from severe but curable intracellular bacterial and viral diseases. Both were homozygous for a missense STAT1 mutation: g.C2086T (P696S). This STAT1 allele impaired the splicing of STAT1 mRNA, probably by disrupting an exonic splice enhancer. The misspliced forms were not translated into a mature protein. The allele was hypofunctional, because residual full-length mRNA production resulted in low but detectable levels of normally functional STAT1 proteins. The P696S amino acid substitution was not detrimental. The patients’ cells, therefore, displayed impaired but not abolished responses to both IFN-α and IFN-γ. We also show that recessive STAT1 deficiencies impaired the IL-27 and IFN-λ1 signaling pathways, possibly contributing to the predisposition to bacterial and viral infections, respectively. Partial recessive STAT1 deficiency is what we believe to be a novel primary immunodeficiency, resulting in impairment of the response to at least 4 cytokines (IFN-α/β, IFN-γ, IFN-λ1, and IL-27). It should be considered in patients with unexplained, severe, but curable intracellular bacterial and viral infections.

Authors

Ariane Chapgier, Xiao-Fei Kong, Stéphanie Boisson-Dupuis, Emmanuelle Jouanguy, Diana Averbuch, Jacqueline Feinberg, Shen-Ying Zhang, Jacinta Bustamante, Guillaume Vogt, Julien Lejeune, Eleonore Mayola, Ludovic de Beaucoudrey, Laurent Abel, Dan Engelhard, Jean-Laurent Casanova

×

Figure 10

The IL-27 and IFN-λ1 pathways are STAT1 dependent.

Options: View larger image (or click on image) Download as PowerPoint
The IL-27 and IFN-λ1 pathways are STAT1 dependent.
(A) IFIT1 mRNA in EBV...
(A) IFIT1 mRNA in EBV-B cells from C+/+, P1, and C–/– after stimulation for 1.5, 2, and 2.5 hours with 20 ng/ml IFN-λ1 or no stimulation. Results are normalized with respect to GUS mRNA and are expressed as multiples (fold induction) of the unstimulated value ± SD. *P < 0.05, **P < 0.01 when compared to C+/+ (Supplemental Table 2). The experiment shown is representative of 3 independent experiments. (B) EMSA with nuclear extracts (5 μg) from EBV-B cells from H, C+/+, P1, P2, C+/–, and C–/– not stimulated or stimulated (S) for 30 minutes with 100 ng/ml IL-27. (B and C) Radiolabeled GAS probes were used. For supershift experiments, IL-27–stimulated nuclear extracts from C+/+ were first incubated with antibodies specific for STAT1, STAT2, STAT3, STAT4, the corresponding isotypic antibodies (Iso), or with a non-radiolabeled probe (C). (C) The experiments shown are representative of 2 to 3 independent experiments. Quantification by PhosphoImager SI (Molecular Dynamics), using the GAS probe, of the response to 100 ng/ml IL-27. Each independent experiment is shown in a different color. The responses are expressed as percentages of the positive control response (taken as 100%). (D) Abundance of IRF1 mRNA in EBV-B cells from C+/+, P1, P2, and C–/–. The cells were either not stimulated or stimulated with 100 ng/ml IL-27 for 1 hour. The results are normalized with respect to GUS mRNA and are expressed as multiples (fold induction) of the unstimulated value ± SD. **P < 0.01, ***P < 0.001 when compared to C+/+. The exact P values are reported in Supplemental Table 2. The experiment shown is representative of 2 independent experiments.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts